Does ofloxacin protect against BCG-related toxic effects in patients with bladder cancer? Commentary

Nature Clinical Practice Urology

Volumn 4, Issue 6, 2007, Pages 304-305

  O'Donnell, Michael ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CORTICOSTEROID; OFLOXACIN; PLACEBO; TUBERCULOSTATIC AGENT;

ANTINEOPLASTIC ACTIVITY; BLADDER BIOPSY; BLADDER CANCER; CANCER GROWTH; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYSTITIS; DRUG EFFICACY; DRUG FEVER; DRUG TOLERABILITY; DRUG WITHDRAWAL; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SEPSIS; SHORT COURSE THERAPY; SHORT SURVEY; SYSTEMIC DISEASE; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; URINARY TRACT INFECTION; URINE CYTOLOGY;

EID: 34250173521     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro0781     Document Type: Short Survey

References (3)

1. Bohle A et al. (1996) The quality of life during intravesical bacillus Calmette-Guerin therapy. J Urol 155: 1221-1226
2. Smith JA Jr et al. (1999) Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol 162: 1697-1701
3. van der Meijden AP et al. (2001) Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: A European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol 166: 476-481